Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2022
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Thomas Malley Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+33.08%
|
-
|
|
Jun 22
2022
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+50.0%
|
-
|
|
Jun 22
2022
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+0.6%
|
-
|
|
Jun 22
2022
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
83,499
+1.42%
|
-
|
|
Jun 22
2022
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+50.0%
|
-
|
|
Jun 22
2022
|
Xiaobin Wu President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
187,876
+15.98%
|
-
|
|
Jun 22
2022
|
Julia Aijun Wang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,377
+29.83%
|
-
|
|
Jun 22
2022
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
125,255
+7.66%
|
-
|
|
Jun 22
2022
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
334,009
+13.89%
|
-
|
|
Jun 22
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
66,768
+33.07%
|
-
|
|
Jun 21
2022
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,010
-100.0%
|
$145,440
$144.36 P/Share
|
|
Jun 21
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
723
-100.0%
|
$107,727
$149.01 P/Share
|
|
Jun 17
2022
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
578
-36.4%
|
$80,342
$139.6 P/Share
|
|
Jun 17
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
445
-38.1%
|
$61,855
$139.4 P/Share
|
|
Jun 17
2022
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
161
-100.0%
|
$21,896
$136.64 P/Share
|
|
Jun 06
2022
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
3,410
-100.0%
|
$480,810
$141.99 P/Share
|
|
Jun 06
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
660
-100.0%
|
$93,720
$142.0 P/Share
|
|
May 17
2022
|
Lai Wang Global Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,233,947
+38.97%
|
$2,467,894
$2.89 P/Share
|
|
May 05
2022
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
6,725
-41.65%
|
$1,109,625
$165.7 P/Share
|
|
Feb 28
2022
|
Julia Aijun Wang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,750
+30.11%
|
-
|
|
Dec 15
2021
|
Xiaobin Wu President and COO |
BUY
Grant, award, or other acquisition
|
Indirect |
0
|
$0
$30.13 P/Share
|
|
Dec 15
2021
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Indirect |
0
|
$0
$30.13 P/Share
|
|
Dec 14
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-48.7%
|
$418,500
$279.11 P/Share
|
|
Dec 14
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Dec 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,049
-75.26%
|
$376,591
$359.89 P/Share
|
|
Nov 30
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
1,049
+50.0%
|
-
|
|
Nov 30
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
14,820
+8.47%
|
-
|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-27.13%
|
$571,500
$381.37 P/Share
|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Nov 09
2021
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
2,334
-37.82%
|
$858,912
$368.03 P/Share
|
|
Nov 08
2021
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
7,666
-19.15%
|
$2,690,766
$351.79 P/Share
|
|
Nov 08
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
9,000
-26.41%
|
$3,150,000
$350.8 P/Share
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
BUY
Bona fide gift
|
Indirect |
58,188
+50.0%
|
-
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Indirect |
58,188
-100.0%
|
-
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-41.36%
|
$558,000
$372.39 P/Share
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Sep 28
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Direct |
58,188
-25.0%
|
-
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
6,000
-30.64%
|
$2,394,000
$399.96 P/Share
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$714,000
$119.96 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,158
-51.27%
|
$9,887,724
$378.57 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
190,203
-9.87%
|
$5,515,887
$29.31 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,877
-41.69%
|
$13,862,982
$366.33 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
157,600
-6.5%
|
$4,412,800
$28.22 P/Share
|
|
Sep 13
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
12,901
-46.67%
|
$4,631,459
$359.46 P/Share
|
|
Sep 10
2021
|
Amgen Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
165,529
+0.87%
|
$49,989,758
$302.06 P/Share
|
|
Sep 02
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
545
-100.0%
|
$178,215
$327.18 P/Share
|
|
Sep 02
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,499
-35.78%
|
$8,035,672
$328.65 P/Share
|